Constructing a value-based healthcare system for hypertensive patients through changing payment mode: evidence from a comparative study in rural China.

Abstract:

OBJECTIVE:To construct a value-based healthcare system for rural Chinese hypertensive patients through an increasing outpatient care reimbursement ratio. METHODS:This comparative study sampled two similar counties, Dangyang County and Zhijiang County, in Hubei Province of China, as the intervention group and the control group, respectively. The Social Health Insurance Fund of the intervention group budgeted 600 yuan per capita per year to insured patients with third stage hypertension to cover their outpatient expenditures, while the outpatient expenditures of the control group were not covered by its Social Health Insurance Fund. The inpatient expenditure reimbursement policies in both groups were not adjusted during the study. Value improvement in this study was defined as reduction in medical costs and improvement in health outcomes within the pilot healthcare system. A propensity score matching model combined with a difference-in-differences model was used to estimate the changes in medical costs and health outcomes. RESULTS:In total, 1,673 pairs of patients were enrolled into statistical analysis after the propensity score matching. The intervention increased per capita annual outpatient expenditure by 81.2 (+31.8%) yuan (p > .05), but decreased the per capita annual inpatient expenditure and total medical expenditure by 475.4 (-40.7%) yuan and 394.2 (-27.7%) yuan, respectively (p < .05). Accordingly, the per capita annual total medical expenditure reimbursement decreased by 192.3 (-28.5%) yuan (p < .05), and the per capita annual total out-of-pocket expenditure by 201.9 (-29.9%) yuan (p < .05). The diastolic blood pressure of the intervention group decreased significantly by 2.9 mmHg (p < .05), but no significant change was found in systolic blood pressure and prevalence of hypertension complications (p > .05). CONCLUSION:Increasing the outpatient expenditures, the reimbursement ratio was beneficial to the value of the healthcare system for hypertensive patients. Outpatient care for patients with chronic diseases should be prioritized for rural China and healthcare settings with inadequate health insurance funds.

journal_name

J Med Econ

authors

Miao Y,Yuan X,Gu J,Zhang L,He R,Sandeep S,Wu J

doi

10.1080/13696998.2018.1558864

subject

Has Abstract

pub_date

2019-03-01 00:00:00

pages

245-251

issue

3

eissn

1369-6998

issn

1941-837X

journal_volume

22

pub_type

杂志文章
  • Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.

    abstract:OBJECTIVE:To assess the cost-effectiveness of panitumumab in combination with mFOLFOX6 (oxaliplatin, 5-fluorouracil, and leucovorin) vs bevacizumab in combination with mFOLFOX6 as first-line treatment of patients with wild-type RAS metastatic colorectal cancer (mCRC) in Spain. METHODS:A semi-Markov model was developed...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.1080/13696998.2017.1285780

    authors: Rivera F,Valladares M,Gea S,López-Martínez N

    更新日期:2017-06-01 00:00:00

  • Effects of innovation and insurance coverage on price elasticity of demand for prescription drugs: some empirical lessons in pharmacoeconomics.

    abstract:AIM:Prescription drug prices in the United States are considered rather extreme. Americans spend over $460 billion on drugs annually, or almost 17 percent of total national healthcare spending. How innovation incentives and insurance coverage drive pricing, diffusion, and utilization of drugs, under conditions of risk ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1772797

    authors: Mendoza RL

    更新日期:2020-09-01 00:00:00

  • Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States.

    abstract:OBJECTIVE:This study evaluated the overall burden of illness of chemotherapy-induced nausea and vomiting (CINV) and associated all-cause costs from a hospital's perspective (costs to the hospital) in patients with cancer treated with chemotherapy (CT) in the US hospital outpatient setting. METHODS:Patients with a canc...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.547237

    authors: Craver C,Gayle J,Balu S,Buchner D

    更新日期:2011-01-01 00:00:00

  • Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.

    abstract:OBJECTIVE:To assess the cost-effectiveness of insulin detemir compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin treatment in people with type 2 diabetes mellitus (T2DM) in Denmark, Finland, Norway, and Sweden. METHODS:Efficacy and safety data were derived from a 20-week multi-centre random...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.3111/13696998.2013.768999

    authors: Ridderstråle M,Jensen MM,Gjesing RP,Niskanen L

    更新日期:2013-01-01 00:00:00

  • A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.

    abstract:OBJECTIVES:To perform a cost-utility analysis of a new formulation of mesalazine (Mezavant XL, MMX mesalazine) versus an existing oral mesalazine (Asacol; mesalazine) from the UK National Health Service perspective. METHODS:A 5-year Markov cohort model was developed. Costs were obtained from the literature and utiliti...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990903562861

    authors: Brereton N,Bodger K,Kamm MA,Hodgkins P,Yan S,Akehurst R

    更新日期:2010-03-01 00:00:00

  • Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom.

    abstract:OBJECTIVES:To determine the cost effectiveness of sevelamer vs calcium carbonate in patients with chronic kidney disease and not on dialysis (CKD-ND) from the perspective of the National Health Service (NHS) in the UK. METHODS:A Markov decision analytic model was developed to estimate (1) total life years (LYs), quali...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.792267

    authors: Thompson M,Bartko-Winters S,Bernard L,Fenton A,Hutchison C,Di Iorio B

    更新日期:2013-01-01 00:00:00

  • A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK.

    abstract:AIM:The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes over a 36-month period in patients with type 2 diabetes initiated on NPH or long-acting insulin analogs. METHODS:Electronic patient data from 479 general practices in the UK (THIN database) were examined for new users of ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2014.991788

    authors: Idris I,Gordon J,Tilling C,Vora J

    更新日期:2015-04-01 00:00:00

  • Within trial cost-utility analysis of disease management program for patients hospitalized with atrial fibrillation: results from the SAFETY trial.

    abstract::Background: The potential impact of disease management to optimize quality of care, health outcomes, and total healthcare costs across a range of cardiac disease states is unknown. Methods: A trial-based cost-utility analysis was conducted alongside a randomized controlled trial of 335 patients with chronic, non-valvu...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1080/13696998.2019.1631831

    authors: Byrnes J,Ball J,Gao L,Kai Chan Y,Kularatna S,Stewart S,Scuffham PA

    更新日期:2019-09-01 00:00:00

  • The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment.

    abstract:OBJECTIVE:To critically evaluate published cost-effectiveness studies of novel drug products requiring less-frequent medication dosing compared to conventional formulations of the same drug substance. METHODS:A search was conducted in the Medline and Embase databases for cost-effectiveness studies published before May...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,评审

    doi:10.3111/13696991003757500

    authors: Cheng MM,Alfonso R,Best JH,Garrison LP,Bruhn D,Veenstra DL

    更新日期:2010-01-01 00:00:00

  • Modelling the health economic impact of managing cow milk allergy in South Africa.

    abstract:OBJECTIVE:To quantify the health economic impact of managing cow milk allergy (CMA) in South Africa, from the perspective of healthcare insurers in both the private and public sectors and parents/carers of CMA sufferers. METHODS:A decision model depicting the management of CMA in South Africa was constructed, using in...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.482904

    authors: Sladkevicius E,Guest JF

    更新日期:2010-01-01 00:00:00

  • Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.

    abstract:OBJECTIVES:Atazanavir (ATV) and darunavir (DRV) are protease inhibitors approved for HIV treatment in combination with ritonavir (/r). The objectives of this study were to compare persistence (time to treatment discontinuation/modification), adherence, and healthcare costs among patients with human immunodeficiency vir...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1128942

    authors: Farr AM,Johnston SS,Ritchings C,Brouillette M,Rosenblatt L

    更新日期:2016-01-01 00:00:00

  • How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?

    abstract:BACKGROUND:Efficient use of government funding has been increasingly relevant for the success and sustainability of ongoing health-system reform in China; however, as there is no generic substitution policy, patients and basic health-insurance programs pay more for public-preferred brand originators. Such phenomenon is...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2016.1181641

    authors: Sun J,Ren L,Wirtz V

    更新日期:2016-09-01 00:00:00

  • Annual cost of relapses and relapse-related hospitalizations in adults with schizophrenia: results from a 12-month, double-blind, comparative study of lurasidone vs quetiapine extended-release.

    abstract:PURPOSE:To model the economic impact of annual relapses/relapse-related hospitalizations among adults with schizophrenia treated with lurasidone or quetiapine extended-release (XR). METHODS:A probabilistic model estimating per-patient-per-year (PPPY) direct mental healthcare (MH) cost differences due to relapses/relap...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696998.2013.809353

    authors: Rajagopalan K,O'Day K,Meyer K,Pikalov A,Loebel A

    更新日期:2013-08-01 00:00:00

  • Using observational analysis of multiple sclerosis relapse to design outcomes-based contracts for disease-modifying drugs: a feasibility assessment.

    abstract:OBJECTIVE:To assess predictors and costs of multiple sclerosis (MS) relapse, a potential outcome measure in payer-manufacturer risk-sharing agreements for disease-modifying drugs (DMDs). METHODS:A retrospective cohort analysis of medical/pharmacy claims was used. Study patients had ≥1 DMD (interferon beta, glatiramer,...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2013.823868

    authors: Lage MJ,Carroll CA,Fairman KA

    更新日期:2013-09-01 00:00:00

  • The economic burden associated with SSRI treatment failure in a managed care population.

    abstract:OBJECTIVE:The objective of this study was to describe the economic burden to managed care associated with failure of selective serotonin reuptake inhibitor (SSRI) therapy in terms of direct medical costs. METHODS:A retrospective analysis of the PharMetrics database, a national managed care medical and pharmacy claims ...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990802522339

    authors: Balkrishnan R,Joish VN,Yang T,Jayawant SS,Mullins CD

    更新日期:2008-01-01 00:00:00

  • Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events.

    abstract::Aims: Cumulative exogenous factor VIII (FVIII) exposure is an important predictor of developing neutralizing antibodies (inhibitors) to FVIII in patients with persons with hemophilia A (PwHA). The aim of this study was to model the costs of emicizumab versus FVIII prophylaxis and total treatment costs for patients wit...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2019.1669614

    authors: Patel AM,Corman SL,Chaplin S,Raimundo K,Sidonio RF

    更新日期:2019-12-01 00:00:00

  • Chronic noncancer pain intensity is inversely related to analgesic adherence in pain clinics.

    abstract:OBJECTIVE:The relationship between chronic noncancer pain (CNCP) control and pain medication (analgesic) adherence has not been widely documented. The primary aim of this study was to evaluate the relationship between pain intensity and the degree of adherence to analgesic medication prescribed in pain clinics. There w...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2011.598202

    authors: Stern A,Sánchez-Magro I,Rull M

    更新日期:2011-01-01 00:00:00

  • Assessing the burden of nocturia in the workplace: the associations between nocturnal voiding, subjective well-being, work engagement and productivity.

    abstract::Aims: Nocturia (getting up at night to urinate, where each urination being followed by sleep or intention to sleep) is a bothersome symptom with potentially negative consequences for individual health and daytime functioning. This study assessed the burden of nocturia in the workplace by investigating associations bet...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1767631

    authors: Hafner M,Andersson FL,Burtea T,van Stolk C,Whitmore M,Yerushalmi E,Troxel WM

    更新日期:2020-09-01 00:00:00

  • Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.

    abstract:OBJECTIVES:To compare demographic and comorbidity profiles and healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% (lidocaine patch) versus patients not treated with the lidocaine patch. Repeat comparison for the subset of patients treated in long-term care (LTC) sett...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.499819

    authors: Kirson NY,Ivanova JI,Birnbaum HG,Wei R,Kantor E,Amy Puenpatom R,Ben-Joseph RH,Summers KH

    更新日期:2010-01-01 00:00:00

  • Reduction in hospital costs and resource consumption associated with the use of advanced topical hemostats during inpatient procedures.

    abstract:OBJECTIVE:The use of hemostatic agents has increased over time for all surgical procedures. The purpose of this study was to evaluate the newer topical absorbable hemostat products Surgicel * Fibrillar † and Surgicel SNoW ‡ (Surgicel advanced products, abbreviated as SAPs) compared to the older product Surgicel Origina...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2015.1017503

    authors: Martyn D,Kocharian R,Lim S,Meckley LM,Miyasato G,Prifti K,Rao Y,Riebman JB,Scaife JG,Soneji Y,Corral M

    更新日期:2015-06-01 00:00:00

  • Risk and cost of infection-related hospitalizations in medicare beneficiaries with comorbid rheumatoid arthritis treated with abatacept versus other targeted disease-modifying anti-rheumatic drugs.

    abstract:OBJECTIVE:This study evaluated infection-related hospitalization risk and cost in tumor necrosis factor inhibitor (TNFi)-experienced and targeted DMARD (tDMARD) naïve rheumatoid arthritis (RA) patients that were treated with abatacept, TNFi, or other non-TNFi. METHODS:This retrospective study used 100% Medicare Fee-fo...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2021.1881525

    authors: Patel V,Pulungan Z,Shah A,Kambhampati M,Lobo F,Petrilla A

    更新日期:2021-01-27 00:00:00

  • Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease.

    abstract:AIMS:To compare patient characteristics, rates, and costs of medically attended falls among patients with Parkinson's disease (PD) and probable PD plus neurogenic orthostatic hypotension (PD + nOH). MATERIALS AND METHODS:MarketScan Commercial and Medicare Supplemental databases (January 1, 2009-December 31, 2013) were...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2017.1284668

    authors: François C,Biaggioni I,Shibao C,Ogbonnaya A,Shih HC,Farrelly E,Ziemann A,Duhig A

    更新日期:2017-05-01 00:00:00

  • The potential value of rapid, cloud-enabled onsite testing for the diagnosis of rheumatoid arthritis in the United States.

    abstract:AIMS:Improvements in information technology have granted the recent development of rapid, cloud-enabled, onsite laboratory testing for rheumatoid arthritis (RA). This study aims to quantify the value to payers of such technologies. MATERIALS AND METHODS:To calculate the value of rapid, cloud-enabled, onsite laboratory...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2018.1502191

    authors: Bognar K,Shafrin J,Brauer M,Zhao L,Hockett R,O'Neil M,Jena A

    更新日期:2018-11-01 00:00:00

  • Healthcare utilization among patients with depression before and after initiating duloxetine in the United Kingdom.

    abstract:OBJECTIVE:Duloxetine is indicated for treatment of major depressive disorders in the UK. While clinical trials have documented its clinical effectiveness, little is known regarding the relationship between duloxetine use and healthcare utilization in community practice. This study quantifies the impact of treatment wit...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.672941

    authors: Shi N,Cao Z,Durden E,Schacht A,Torres A,Happich M

    更新日期:2012-01-01 00:00:00

  • Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.

    abstract:OBJECTIVES:To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. METHODS:Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicar...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.690801

    authors: Copher R,Cerulli A,Watkins A,Laura Monsalvo M

    更新日期:2012-01-01 00:00:00

  • Budget impact analysis of long acting injection for schizophrenia in Japan.

    abstract::Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.1080/13696998.2020.1754229

    authors: Kasahara-Kiritani M,Chaturvedi A,Inagaki A,Wakamatsu A,Jung W

    更新日期:2020-08-01 00:00:00

  • Cost effectiveness of palivizumab in children with congenital heart disease in Germany.

    abstract:OBJECTIVES:To assess the cost effectiveness of palivizumab, a humanised monoclonal antibody, used as prevention against severe respiratory syncytial virus (RSV) infection requiring hospitalisation, in infants with haemodynamically significant congenital heart disease (CHD) in the German healthcare setting. STUDY DESIG...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696990903347172

    authors: Nuijten M,Lebmeier M,Wittenberg W

    更新日期:2009-01-01 00:00:00

  • Cost effectiveness of transcatheter aortic valve replacement compared to medical management in inoperable patients with severe aortic stenosis: Canadian analysis based on the PARTNER Trial Cohort B findings.

    abstract:OBJECTIVE:The only effective treatment for severe aortic stenosis (AS) is valve replacement. However, many patients with co-existing conditions are ineligible for surgical valve replacement, historically leaving medical management (MM) as the only option which has a poor prognosis. Transcatheter Aortic Valve Replacemen...

    journal_title:Journal of medical economics

    pub_type: 杂志文章,随机对照试验

    doi:10.3111/13696998.2013.770747

    authors: Hancock-Howard RL,Feindel CM,Rodes-Cabau J,Webb JG,Thompson AK,Banz K

    更新日期:2013-01-01 00:00:00

  • Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer.

    abstract:OBJECTIVE:Two human papillomavirus (HPV) vaccines are on the market. Based on expected differences in sustained- and cross-protection between the two vaccines, their long-term economic value is modelled and compared for France, Ireland and Italy. METHODS:A Markov cohort model reproducing the natural history of HPV inf...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2010.490481

    authors: Demarteau N,Standaert B

    更新日期:2010-01-01 00:00:00

  • The cost-effectiveness of a new percutaneous ventricular assist device for high-risk PCI patients: mid-stage evaluation from the European perspective.

    abstract:OBJECTIVE:A new and smaller percutaneous ventricular assist device (pVAD, Impella, Abiomed, Danvers, MA) has been developed to provide circulatory support in hemodynamically unstable patients and to prevent hemodynamic collapse during high-risk percutaneous coronary interventions (PCI). The objective of the study was t...

    journal_title:Journal of medical economics

    pub_type: 杂志文章

    doi:10.3111/13696998.2012.762004

    authors: Roos JB,Doshi SN,Konorza T,Palacios I,Schreiber T,Borisenko OV,Henriques JP

    更新日期:2013-01-01 00:00:00